A New Name in Weight-Loss Drugs
Novo Nordisk and Eli Lilly have soared on GLP-1 weight-loss drugs – now Hims & Hers is trying to get in on the action with a more available and affordable option. (00:21) Asit Sharma and Dylan Lewis discuss: - Hims & Hers getting into the business of GLP-1 weight loss injections and what the compound market means for…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Motley Fool Hidden Gems Investing
See all episodes →Similar episodes from other shows
More like Motley Fool Hidden Gems Investing →
Here's How the New Weight Loss Drugs Could Change Everything
JPMorgan’s Sharp Reversal… And The Latest Entry To The Weight Loss Drug Battle 5/20/24
Healthcare is Broken—This Company Wants to Fix It
Novo Nordisk, Eli Lilly and the GLP-1 economy
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.